Parkinson's patients get early access to experimental drug tavapadon
NCT ID NCT07158827
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This program allows eligible people with Parkinson's disease to receive tavapadon, an experimental oral tablet, before it is officially approved. A doctor must decide if the potential benefit outweighs the risks. The program is only available in certain territories and for those who cannot join ongoing clinical trials or have no other suitable treatment options.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- tavapadon (oral tablet)
- What this could lead to
- If successful, this program could offer early access to a new treatment option for Parkinson's disease before it is officially approved.
- What could go wrong
- This is an expanded access program, not a clinical trial, so data on safety and effectiveness is limited. Tavapadon is still investigational and may have unknown risks.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PARKINSON DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Planning ahead: could a simple program transform Parkinson's care?
- Sound waves vs. Parkinson's: can ultrasound calm tremors and stiffness?
- Can a nudge in your chart unlock Life-Saving genetic clues?
- Can MRI reveal the Brain's response to deep brain stimulation?
- Can we outsmart Gaucher's hidden toll on lungs, bones, and brain?
- Could a brain disease change behavior years before diagnosis?